FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival

Cardiovascular Research

Volumn 97, Issue 3, 2013, Pages 393-403

  Puthanveetil, Prasanth ^a   Wan, Andrea ^a   Rodrigues, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cell death; Diabetes; FoxO1; Heart; Metabolism

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR FKHR;

CELL DEATH; CELL METABOLISM; CELL SURVIVAL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; EMBRYONIC STEM CELL; HEART INFARCTION; HEART INJURY; HEART MUSCLE CELL; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW;

APOPTOSIS; CELL SURVIVAL; DIABETIC CARDIOMYOPATHIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INSULIN RESISTANCE; MYOCYTES, CARDIAC; OXIDATIVE STRESS;

EID: 84874237993     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs426     Document Type: Review

References (131)

1. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011;91:79-118.
2. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002;115:18-29.
3. Cebioglu M, Schild HH, Golubnitschaja O. Diabetes mellitus as a risk factor for cancer: stress or viral etiology? Infect Disord Drug Targets 2008;8:76-87.
4. Nolan CJ. Failure of islet beta-cell compensation for insulin resistance causes type 2 diabetes: what causes non-alcoholic fatty liver disease and non-alcoholic steatohepatitis? J Gastroenterol Hepatol 2010;25:1594-1597.
5. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 2007;292:E654-E667.
6. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489- H1506.
7. Diamant M. Current studies of diabetic cardiomyopathy and the advancement of our knowledge: time to learn from history, guidelines, . . . and other disciplines? Eur J Heart Fail 2012;14:115-117.
8. Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 2012;122:1109-1118.
9. Puthanveetil P, Wang Y, Zhang D, Wang F, Kim MS, Innis S et al. Cardiac triglyceride accumulation following acute lipid excess occurs through activation of a FoxO1-iNOS-CD36 pathway. Free Radic Biol Med 2011;51:352-363.
10. Puthanveetil P, Wang Y, Wang F, Kim MS, Abrahani A, Rodrigues B. The increase in cardiac pyruvate dehydrogenase kinase-4 after short-term dexamethasone is controlled by an Akt-p38-forkhead box other factor-1 signaling axis. Endocrinology 2010;151:2306-2318.
11. Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: developing therapeutic inroads with FoxO proteins. Oxidative Med Cell Longevity 2009;2:119-129.
12. Hannenhalli S, Kaestner KH. The evolution of Fox genes and their role in development and disease. Nat Rev Genet 2009;10:233-240.
13. Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, Epstein JA et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006;114:1269-1276.
14. Obsil T, Obsilova V. Structural basis for DNA recognition by FOXO proteins. Biochim Biophys Acta 2011;1813:1946-1953.
15. Obsil T, Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene 2008;27:2263-2275.
16. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011;1813:1938-1945.
17. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep 2009;9:208-214.
18. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380:297-309.
19. Daitoku H, Sakamaki J, Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011;1813: 1954-1960.
20. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. O-GlcNAc modification of FoxO1 increases its transcriptional activity: a role in the glucotoxicity phenomenon? Biochimie 2008;90:679-685.
21. Yamagata K, Daitoku H, Takahashi Y, Namiki K, Hisatake K, Kako K et al. Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 2008;32:221-231.
22. Evans-Anderson HJ, Alfieri CM, Yutzey KE. Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors. Circ Res 2008;102:686-694.
23. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 2005; 7:752-760.
24. Lees SJ, Childs TE, Booth FW. Age-dependent FOXO regulation of p27Kip1 expression via a conserved binding motif in rat muscle precursor cells. Am J Physiol Cell Physiol 2008;295:C1238-C1246.
25. Fan W, Morinaga H, Kim JJ, Bae E, Spann NJ, Heinz S et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J 2010;29:4223-4236.
26. Zhang X, Yalcin S, Lee DF, Yeh TY, Lee SM, Su J et al. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol 2011;13: 1092-1099.
27. Peng SL. Immune regulation by Foxo transcription factors. Autoimmunity 2007;40: 462-469.
28. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011;1813:1978-1986.
29. Issad T, Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008;19:380-389.
30. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005;3:221-229.
31. Kim SY, Yoon J, Ko YS, Chang MS, Park JW, Lee HE et al. Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules. BMC Cancer 2011;11:264.
32. Samarin J, Wessel J, Cicha I, Kroening S, Warnecke C, Goppelt-Struebe M. FoxO proteins mediate hypoxic induction of connective tissue growth factor in endothelial cells. J Biol Chem 2010;285:4328-4336.
33. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F et al. Insulinregulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003;423:550-555.
34. Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008;295:E785-E797.
35. Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM. FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue. Diabetes 2009; 58:1275-1282.
36. Nakae J, Cao Y, Oki M, Orba Y, Sawa H, Kiyonari H et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008;57:563-576.
37. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008;27:2320-2336.
38. Chen F, Zhu Y, Tang X, Sun Y, Jia W, Sun Y et al. Dynamic regulation of PDX-1 and FoxO1 expression by FoxA2 in dexamethasone-induced pancreatic beta-cells dysfunction. Endocrinology 2011;152:1779-1788.
39. Cao Y, Kamioka Y, Yokoi N, Kobayashi T, Hino O, Onodera M et al. Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway. J Biol Chem 2006;281:40242-40251.
40. Hariharan N, Maejima Y, Nakae J, Paik J, Depinho RA, Sadoshima J. Deacetylation of FoxO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ Res 2010;107:1470-1482.
41. Sengupta A, Molkentin JD, Yutzey KE. FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 2009;284:28319-28331.
42. Ferdous A, Battiprolu PK, Ni YG, Rothermel BA, Hill JA. FoxO, autophagy, and cardiac remodeling. J Cardiovasc Transl Res 2010;3:355-364.
43. Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011;17:961-967.
44. Wei D, Tao R, Zhang Y, White MF, Dong XC. Feedback regulation of hepatic gluconeogenesis through modulation of SHP/Nr0b2 gene expression by Sirt1 and FoxO1. Am J Physiol Endocrinol Metab 2011;300:E312-E320.
45. Senokuchi T, Liang CP, Seimon TA, Han S, Matsumoto M, Banks AS et al. Forkhead transcription factors (FoxOs) promote apoptosis of insulin-resistant macrophages during cholesterol-induced endoplasmic reticulum stress. Diabetes 2008;57: 2967-2976.
46. Kim HJ, Kobayashi M, Sasaki T, Kikuchi O, Amano K, Kitazumi T et al. Overexpression of FoxO1 in the hypothalamus and pancreas causes obesity and glucose intolerance. Endocrinology 2012;153:659-671.
47. Plum L, Lin HV, Dutia R, Tanaka J, Aizawa KS, Matsumoto M et al. The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake. Nat Med 2009;15:1195-1201.
48. Zhang J, Tokui Y, Yamagata K, Kozawa J, Sayama K, Iwahashi H et al. Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 2007;50: 1900-1909.
49. Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 2009;58:917-925.
50. Kayal RA, Siqueira M, Alblowi J, McLean J, Krothapalli N, Faibish D et al. TNF-alpha mediates diabetes-enhanced chondrocyte apoptosis during fracture healing and stimulates chondrocyte apoptosis through FOXO1. J Bone Miner Res 2010;25: 1604-1615.
51. Qi D, Pulinilkunnil T, An D, Ghosh S, Abrahani A, Pospisilik JA et al. Single-dose dexamethasone induces whole-body insulin resistance and alters both cardiac fatty acid and carbohydrate metabolism. Diabetes 2004;53:1790-1797.
52. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M. Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol Genet Metab 1998;65: 181-186.
53. Constantin-Teodosiu D, Constantin D, Stephens F, Laithwaite D, Greenhaff PL. The role of FOXO and PPAR transcription factors in diet-mediated inhibition of PDC activation and carbohydrate oxidation during exercise in humans and the role of pharmacological activation of PDC in overriding these changes. Diabetes 2012;61: 1017-1024.
54. Kukimoto-Niino M, Tokmakov A, Terada T, Ohbayashi N, Fujimoto T, Gomi S et al. Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. Acta Crystallogr D Biol Crystallogr 2011;67:763-773.
55. Carley AN, Kleinfeld AM. Fatty acid (FFA) transport in cardiomyocytes revealed by imaging unbound FFA is mediated by an FFA pump modulated by the CD36 protein. J Biol Chem 2011;286:4589-4597.
56. Steinbusch LK, Schwenk RW, Ouwens DM, Diamant M, Glatz JF, Luiken JJ. Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol Life Sci 2011;68:2525-2538.
57. Nicholson AC. Expression of CD36 in macrophages and atherosclerosis: the role of lipid regulation of PPARgamma signaling. Trends Cardiovasc Med 2004;14:8-12.
58. Sfeir Z, Ibrahimi A, Amri E, Grimaldi P, Abumrad N. Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. Prostaglandins leukot Essent Fatty Acids 1997;57:17-21.
59. Habets DD, Coumans WA, El Hasnaoui M, Zarrinpashneh E, Bertrand L, Viollet B et al. Crucial role for LKB1 to AMPKalpha2 axis in the regulation of CD36-mediated long-chain fatty acid uptake into cardiomyocytes. Biochim Biophys Acta 2009;1791: 212-219.
60. Bastie CC, Nahle Z, McLoughlin T, Esser K, Zhang W, Unterman T et al. FoxO1 stimulates fatty acid uptake and oxidation in muscle cells through CD36-dependent and-independent mechanisms. J Biol Chem 2005;280:14222-14229.
61. Lekli I, Mukherjee S, Ray D, Gurusamy N, Kim YH, Tosaki A et al. Functional recovery of diabetic mouse hearts by glutaredoxin-1 gene therapy: role of Akt-FoxO-signaling network. Gene Ther 2010;17:478-485.
62. Munoz JP, Chiong M, Garcia L, Troncoso R, Toro B, Pedrozo Z et al. Iron induces protection and necrosis in cultured cardiomyocytes: role of reactive oxygen species and nitric oxide. Free Radic Biol Med 2010;48:526-534.
63. An D, Kewalramani G, Chan JK, Qi D, Ghosh S, Pulinilkunnil T et al. Metformin influences cardiomyocyte cell death by pathways that are dependent and independent of caspase-3. Diabetologia 2006;49:2174-2184.
64. Chiong M, Wang ZV, Pedrozo Z, Cao DJ, Troncoso R, Ibacache M et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Disease 2011;2:e244.
65. Bustamante-Marin X, Quiroga C, Lavandero S, Reyes JG, Moreno RD. Apoptosis, necrosis and autophagy are influenced by metabolic energy sources in cultured rat spermatocytes. Apoptosis 2012;17:539-550.
66. McCormick J, Knight RA, Barry SP, Scarabelli TM, Abounit K, Latchman DS et al. Autophagy in the stress-induced myocardium. Front Biosci 2012;4:2131-2141.
67. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010;72:19-44.
68. Nishida K, Otsu K. Cell death in heart failure. Circ J 2008;72(Suppl A):A17-A21.
69. Medema RH, Jaattela M. Cytosolic FoxO1: alive and killing. Nat Cell Biol 2010;12: 642-643.
70. Zhao Y, Yang J, Liao W, Liu X, Zhang H, Wang S et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010;12: 665-675.
71. Lockshin RA, Zakeri Z. Caspase-independent cell deaths. Curr Opin Cell Biol 2002;14: 727-733.
72. Assuncao Guimaraes C, Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J Biochem 2004;271:1638-1650.
73. Munoz-Gamez JA, Rodriguez-Vargas JM, Quiles-Perez R, Aguilar-Quesada R, Martin-Oliva D, de Murcia G et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 2009;5:61-74.
74. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008;283:19665-19677.
75. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008;27:6398-6406.
76. Lam D, Levraud JP, Luciani MF, Golstein P. Autophagic or necrotic cell death in the absence of caspase and bcl-2 family members. Biochem Biophys Res Commun 2007; 363:536-541.
77. KuoWW, Chung LC, Liu CT,Wu SP, Kuo CH, Tsai FJ et al. Effects of insulin replacement on cardiac apoptotic and survival pathways in streptozotocin-induced diabetic rats. Cell Biochem Funct 2009;27:479-487.
78. Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam Horm 2004;67:409-426.
79. Ni YG, Wang N, Cao DJ, Sachan N, Morris DJ, Gerard RD et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 2007;104:20517-20522.
80. Yu L, Lenardo MJ, Baehrecke EH. Autophagy and caspases: a new cell death program. Cell Cycle 2004;3:1124-1126.
81. Takemura G, Miyata S, Kawase Y, Okada H, Maruyama R, Fujiwara H. Autophagic degeneration and death of cardiomyocytes in heart failure. Autophagy 2006;2: 212-214.
82. Singletary K, Milner J. Diet, autophagy, and cancer: a review. Cancer Epidemiol Biomarkers Prev 2008;17:1596-1610.
83. Sengupta A, Molkentin JD, Paik JH, DePinho RA, Yutzey KE. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem 2011;286:7468-7478.
84. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20:1-15.
85. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 2006;1757:1371-1387.
86. Han J, Zhong CQ, Zhang DW. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol 2011;12:1143-1149.
87. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009;218:193-202.
88. Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 2011;4:ra20.
89. Tanaka J, Qiang L, Banks AS, Welch CL, Matsumoto M, Kitamura T et al. Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. Diabetes 2009;58:2344-2354.
90. White PJ, Charbonneau A, Cooney GJ, Marette A. Nitrosative modifications of protein and lipid signaling molecules by reactive nitrogen species. Am J Physiol Endocrinol Metab 2010;299:E868-E878.
91. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-534.
92. Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B. Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: relevance to its mechanism of action. Exp Cell Res 2011;317:1359-1367.
93. Tristan C, Shahani N, Sedlak TW, Sawa A. The diverse functions of GAPDH: views from different subcellular compartments. Cell Signal 2011;23:317-323.
94. Quijano C, Hernandez-Saavedra D, Castro L, McCord JM, Freeman BA, Radi R. Reaction of peroxynitrite with Mn-superoxide dismutase. Role of the metal center in decomposition kinetics and nitration. J Biol Chem 2001;276:11631- 11638.
95. Hesslinger C, Strub A, Boer R, Ulrich WR, Lehner MD, Braun C. Inhibition of inducible nitric oxide synthase in respiratory diseases. Biochem Soc Trans 2009;37: 886-891.
96. Zhou X, Yang W, Li J. Ca2+-and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide- stimulated rat peritoneal macrophages. J Biol Chem 2006;281:31337-31347.
97. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
98. Leon L, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis. Nitric Oxide 2008;19:77-83.
99. Nakamura T, Lipton SA. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ 2011;18:1478-1486.
100. Martinez-Ruiz A, Lamas S. Signalling by NO-induced protein S-nitrosylation and Sglutathionylation: convergences and divergences. Cardiovasc Res 2007;75:220-228.
101. Sen N, Hara MR, Kornberg MD, Cascio MB, Bae BI, Shahani N et al. Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol 2008;10:866-873.
102. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
103. Larson MG. Assessment of cardiovascular risk factors in the elderly: the Framingham heart study. Stat Med 1995;14:1745-1756.
104. Borden WB, Davidson MH. Updating the assessment of cardiac risk: beyond Framingham. Rev Cardiovasc Med 2009;10:63-71.
105. Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res 1992;26:913-922.
106. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104-E1113.
107. Wang J, Song Y, Wang Q, Kralik PM, Epstein PN. Causes and characteristics of diabetic cardiomyopathy. Rev Diab Stud 2006;3:108-117.
108. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010;11:31-39.
109. Langlais P, Yi Z, Finlayson J, Luo M, Mapes R, De Filippis E et al. Global IRS-1 phosphorylation analysis in insulin resistance. Diabetologia 2011;54:2878-2889.
110. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 2009;296:E581-E591.
111. Tanti JF, Gual P, Gremeaux T, Gonzalez T, Barres R, Le Marchand-Brustel Y. Alteration in insulin action: role of IRS-1 serine phosphorylation in the retroregulation of insulin signalling. Ann Endocrinol 2004;65:43-48.
112. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M et al. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calciumrelease channels. Diabetes 2003;52:1825-1836.
113. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 2003;278:44230-44237.
114. Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 2004;6:424-429.
115. Tan Y, Li X, Prabhu SD, Brittian KR, Chen Q, Yin X et al. Angiotensin II plays a critical role in alcohol-induced cardiac nitrative damage, cell death, remodeling, and cardiomyopathy in a protein kinase C/nicotinamide adenine dinucleotide phosphate oxidase-dependent manner. J Am Coll Cardiol 2012;59:1477-1486.
116. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
117. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999;43:860-878.
118. Stangl V, Baumann G, Stangl K, Felix SB. Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res 2002;53:12-30.
119. Coggins M, Rosenzweig A. The fire within: cardiac inflammatory signaling in health and disease. Circ Res 2012;110:116-125.
120. Takahashi HK, Cambiaghi TD, Luchessi AD, Hirabara SM, Vinolo MA, Newsholme P et al. Activation of survival and apoptotic signaling pathways in lymphocytes exposed to palmitic acid. J Cell Physiol 2012;227:339-350.
121. Basseri S, Austin RC. Endoplasmic reticulum stress and lipid metabolism: mechanisms and therapeutic potential. Biochem Res Int 2012;841362:1-13.
122. Wang X, Wu H, Chen H, Liu R, Liu J, Zhang T et al. Does insulin bolster antioxidant defenses via the extracellular signal-regulated kinases-protein kinase B-nuclear factor erythroid 2 p45-related factor 2 pathway? Antioxid Redox Signal 2012;16:1061-1070.
123. Hemi R, Yochananov Y, Barhod E, Kasher-Meron M, Karasik A, Tirosh A et al. p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: a novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance. Diabetes 2011;60:1134-1145.
124. Kiraly MA, Campbell J, Park E, Bates HE, Yue JT, Rao V et al. Exercise maintains euglycemia in association with decreased activation of c-Jun NH2-terminal kinase and serine phosphorylation of IRS-1 in the liver of ZDF rats. Am J Physiol Endocrinol Metab 2010;298:E671-E682.
125. Bhargava P, Lee CH. Role and function of macrophages in the metabolic syndrome. Biochem J 2012;442:253-262.
126. Kim MS, Kewalramani G, Puthanveetil P, Lee V, Kumar U, An D et al. Acute diabetes moderates trafficking of cardiac lipoprotein lipase through p38 mitogen-activated protein kinase-dependent actin cytoskeleton organization. Diabetes 2008;57:64-76.
127. Cresci S. Pharmacogenetics of the PPAR genes and cardiovascular disease. Pharmacogenomics 2007;8:1581-1595.
128. Nikolaidis LA, Levine TB. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiol Rev 2004;12:158-170.
129. Wang Y, Puthanveetil P, Wang F, Kim MS, Abrahani A, Rodrigues B. Severity of diabetes governs vascular lipoprotein lipase by affecting enzyme dimerization and disassembly. Diabetes 2011;60:2041-2050.
130. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A et al. AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 2007;42:333-342.
131. Sengupta A, Chakraborty S, Paik J, Yutzey KE, Evans-Anderson HJ. FoxO1 is required in endothelial but not myocardial cell lineages during cardiovascular development. Dev Dyn 2012;241:803-813.